Previous 10 | Next 10 |
2023-11-07 01:36:02 ET Summary BioMarin's stock has fallen over 12% in recent months, but the pullback presents an opportunity to accumulate positions. 3Q results showed lower-than-expected revenues, but adjusted EBITDA and EPS beat market expectations. Voxzogo's sales are gro...
2023-11-02 11:08:17 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin appoints Alexander Hardy as president and chief executive officer BioMarin Pharmaceutical Q3 2023 Earnings Preview For further details see: BioMarin Pha...
2023-11-01 19:36:03 ET Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Conference Call November 01, 2023, 04:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer -...
2023-11-01 16:29:22 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View BioMarin appoints Alexander Hardy as president and chief executive officer BioMarin Pharmaceutical Q3 2023 Earnings Previ...
2023-11-01 16:27:34 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View BioMarin Pharmaceutical Q3 2023 Earnings Preview Bernstein upgrades BioMarin to market perform, citing valuation ...
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year PR Newswire • Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO ® and ROCTAVIAN ® ...
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer PR Newswire Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaim é Served as CE...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
BioMarin Pharmaceutical Inc. (BMRN) is expected to report $0.28 for Q3 2023
2023-10-23 16:05:17 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript FDA approves use of BioMarin drug Voxzogo in childr...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...